Performance status-0 - Asymptomatic - Page 14 of 18 Posts on Medivizor
Navigation Menu

Performance status-0 – Asymptomatic Posts on Medivizor

Can adverse events after hormone therapy predict survival in patients with breast cancer?

Can adverse events after hormone therapy predict survival in patients with breast cancer?

Posted by on Jul 2, 2013 in Breast cancer | 0 comments

In a nutshell The aim of this study was to investigate the relationship between survival outcomes and specific adverse events (AEs) in patients after menopause (postmenopausal) with breast cancer treated with hormone therapy. Some background Most breast cancers grow in response to estrogen, the main female sex hormone. Therefore, hormone therapy...

Read More

Can removal of the axillary lymph nodes be avoided if there is minimal involvement of the sentinel lymph nodes in breast cancer?

Can removal of the axillary lymph nodes be avoided if there is minimal involvement of the sentinel lymph nodes in breast cancer?

Posted by on Jun 29, 2013 in Breast cancer | 0 comments

In a nutshell This study tested the effect of complete axillary lymph node removal, on survival without recurrence of the cancer (called disease free survival or DFS) in patients with breast cancer.  Some background Lymph nodes are small organs which are part of the immune system. They filter fluid called lymph. Lymph can be thought of as the...

Read More

Comparing survival after mastectomy and lumpectomy in patients with early-stage breast cancer

Posted by on Jun 28, 2013 in Breast cancer | 0 comments

In a nutshell The study compared survival rates in patients with early stage breast cancer treated with mastectomy versus lumpectomy plus radiation therapy. Some background Most breast cancers grow in response to female hormones (estrogen or progesterone), via their receptor (a protein found on the surface of the cancer cells). These cancers are...

Read More

A review on surgery as treatment for elderly patients with rectal cancer

A review on surgery as treatment for elderly patients with rectal cancer

Posted by on Jun 27, 2013 in Colorectal cancer | 0 comments

In a nutshell This review summarizes the outcomes of surgical treatment for rectal cancer in elderly patients. Some background The risk of developing rectal cancer increases with age. Up to half of the patients with rectal cancer are 75 or older. However, elderly patients also have other health problems, thus they are exposed to a higher risk of...

Read More

Wait-and-see policy in patients with rectal cancer treated with chemoradiotherapy

Wait-and-see policy in patients with rectal cancer treated with chemoradiotherapy

Posted by on Jun 26, 2013 in Colorectal cancer | 0 comments

In a nutshell The purpose of this study was to evaluate the safety and utility of a wait and see policy in patients with rectal cancer treated with chemoradiotherapy.  Some background Treatment options for patients with rectal cancer (cancer in the final part of the large bowel) is chemotherapy with or without radiotherapy (together called...

Read More

Phase 3 clinical trial of evaluating lapatinib in patients with HER2 positive breast cancer

Phase 3 clinical trial of evaluating lapatinib in patients with HER2 positive breast cancer

Posted by on Jun 25, 2013 in Breast cancer | 0 comments

In a nutshell This phase 3 clinical trial investigated the safety and efficacy of lapatinib (Tykerb) in women with HER2 positive early-stage breast cancer. Some background HER2-positive (HER2+) breast cancer is a type of cancer where a protein named human epidermal growth factor receptor 2 (HER2) is present on the surface of the breast...

Read More

Evaluating chemotherapy options for patients with triple negative breast cancer

Evaluating chemotherapy options for patients with triple negative breast cancer

Posted by on Jun 17, 2013 in Breast cancer | 0 comments

In a nutshell This article looked at the use of a platinum based chemotherapy (cisplatin) to a non-platinum based chemotherapy for patients with triple negative breast cancer. Some background Most breast cancers have on their surface some proteins called receptors that help the breast cancers grow. These can be hormone receptors (estrogen or...

Read More

Phase 3 clinical trial evaluating the safety and efficacy of adding everolimus to exemestane therapy in patients with hormone receptor-positive advanced breast cancer

Phase 3 clinical trial evaluating the safety and efficacy of adding everolimus to exemestane therapy in patients with hormone receptor-positive advanced breast cancer

Posted by on Jun 1, 2013 in Breast cancer | 0 comments

In a nutshell This phase 3 clinical trial tested whether everolimus (a non-hormonal treatment) added to hormone therapy with exemestane improved survival in patients with advanced breast cancer (BCa).  Some background Some BCa are fueled by female sex hormones (estrogen or progesterone) that help them grow. These types of cancer are called...

Read More

Evaluating the benefits of laparoscopy in determining the extent of peritoneal carcinomatosis for patients with colorectal cancer

Evaluating the benefits of laparoscopy in determining the extent of peritoneal carcinomatosis for patients with colorectal cancer

Posted by on May 13, 2013 in Colorectal cancer | 0 comments

In a nutshell This article evaluated whether the use of a minimally invasive diagnostic technique called laparoscopy before surgery to treat peritoneal carcinomatosis improves the selection of patients who can benefit the most from treatment. The authors of the study found that laparoscopy can be used to select patients for whom surgery may be a...

Read More

Comparing the outcomes of laparoscopic versus open surgery in patients with colorectal cancer

Posted by on May 9, 2013 in Colorectal cancer | 0 comments

In a nutshell This study compared the short- and long-term outcomes of two types of surgery for patients with colorectal cancer (CRC): open surgery (OS) versus laparoscopic surgery (LS). LS led to less pain following surgery, shorter hospital stays, faster recovery times, and improved survival rates. Some background CRC is very common,...

Read More